About Careers Internship MedBlog Contact us

GlaxoSmithKline for Malaria Vaccine’s Clinical Trials in Africa Next Year

by Tanya Thomas on November 12, 2008 at 5:22 PM
GlaxoSmithKline for Malaria Vaccine’s Clinical Trials in Africa Next Year

The pharmaceutical biggie GlaxoSmithKline announced its proposed launch of final clinical trials for an anti-malaria vaccine in seven African countries to kick-off in January.

"This is the most advanced vaccine, and the only one today that has been shown effective against malaria in infants and children in Africa," said Joe Cohen, who created the vaccine after two decades of work for GlaxoSmithKline.


Studies in Mozambique on children under five found that the vaccine, called RTS,S, was 30-35 percent effective against benign cases of malaria and 50 percent effective against severe cases, over a period of about three years.

"With 30-35 percent effectiveness, that would prevent 100 million cases of illness a year ... and suggests that several million lives could be saved," Cohen told AFP, noting that malaria spells death for nearly one million children every year.

In Mozambique, the vaccine also reduced the number of hospitalizations from malaria, said Christian Loucq, director of the Malaria Vaccine Initiative, which is financed in part by the Bill et Melinda Gates Foundation.

The clinical trials will take place at 11 sites in Kenya, Malawi, Mozambique, Gabon, Ghana, Burkina Faso et Tanzania.

About 16,000 children will take part in the study, which includes African scientists, and the first trials should begin in January in some countries, Loucq said.

"This is a vaccine designed to activate the immune system in such a way ... that it destroys the parasite very quickly when it is in the blood or the liver, before it reaches the red blood cells," Cohen explained.

The phase III trial, the last step before seeking regulatory approval, would allow sales of the vaccine possibly in 2012, if the results are conclusive.

Developing the vaccine has cost some 500 million dollars i.e. 392 millions euros, Cohen and Loucq said.

Source: AFP
Font : A-A+



Recommended Readings

Latest Tropical Disease News

Rare Zika Case Emerges in Cambodia After Seven Years
The Ministry of Health (MoH) in Cambodia has reported the first Zika virus case in the country since 2016.
Global Spread of Mpox Virus Persists: Cases Reported in China and Thailand
The WHO has assessed the risk of monkeypox for the general population in countries not previously impacted by the current outbreak as low.
Understanding Nipah Virus: Droplet Transmission and Its Lethality at 40-70%
Nipah is a zoonotic virus, meaning it can be transmitted from animals to humans. Fruit bats serve as the natural reservoirs for Nipah virus.
Tamil Nadu Reports Zero Nipah Virus Cases
Nipah Virus (NiV) or Hendra virus is a deadly virus that spreads via contact with the saliva, urine, or excreta of fruit bats or pigs.
Nipah Virus Outbreak: 2 Fatalities Trigger Emergency Response in Kozhikode
Nipah virus is mainly a zoonotic disease, transferring from animals to humans, and can also spread via contaminated food or contact with infected individuals.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

GlaxoSmithKline for Malaria Vaccine’s Clinical Trials in Africa Next Year Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests